Robert Cohen - Stryker CTO Replacement
| SYK Stock | EUR 348.50 4.30 1.25% |
Insider
Robert Cohen is CTO Replacement of Stryker
| Phone | 269 385 2600 |
| Web | https://www.stryker.com |
Robert Cohen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Cohen against Stryker stock is an integral part of due diligence when investing in Stryker. Robert Cohen insider activity provides valuable insight into whether Stryker is net buyers or sellers over its current business cycle. Note, Stryker insiders must abide by specific rules, including filing SEC forms every time they buy or sell Stryker'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Cohen over a month ago Acquisition by Robert Cohen of 1823107 shares of Zomedica Pharmaceuticals at 0.13 subject to Rule 16b-3 | ||
Robert Cohen over three months ago Acquisition by Robert Cohen of 3324 shares of Stride subject to Rule 16b-3 | ||
Robert Cohen over six months ago Disposition of 543750 shares by Robert Cohen of Zomedica Pharmaceuticals at 0.23 subject to Rule 16b-3 |
Stryker Management Efficiency
The company has return on total asset (ROA) of 0.0618 % which means that it generated a profit of $0.0618 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1498 %, meaning that it generated $0.1498 on every $100 dollars invested by stockholders. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mark Ploof | Medtronic PLC | N/A | |
| John Sorenson | Boston Scientific | 55 | |
| Christine McCauley | Edwards Lifesciences | 58 | |
| Larry Wood | Edwards Lifesciences | 57 | |
| Christopher Toth | Siemens Healthineers AG | 44 | |
| Dirksen Lehman | Edwards Lifesciences | N/A | |
| Donald Bobo | Edwards Lifesciences | 61 | |
| Jodi Eddy | Boston Scientific | 50 | |
| Melissa Brotz | Abbott Laboratories | N/A | |
| Elaine Leavenworth | Abbott Laboratories | 64 | |
| MSc MD | Medtronic PLC | N/A | |
| Andre Hartung | Siemens Healthineers AG | N/A | |
| Jeffrey Mirviss | Boston Scientific | 57 | |
| Julie Coletti | Align Technology | 54 | |
| JeanLuc Lemercier | Edwards Lifesciences | 66 | |
| Vamsi Pudipeddi | Align Technology | 51 | |
| Jennifer OlsonWilk | Align Technology | 45 | |
| Bernhard Montag | Siemens Healthineers AG | 54 | |
| Sean Lennon | Medtronic PLC | N/A | |
| Catherine Jennings | Boston Scientific | N/A | |
| Carsten Bertram | Siemens Healthineers AG | N/A | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0618 |
Stryker Leadership Team
Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Cohen, CTO Replacement | ||
| Alan Douville, Chief VP | ||
| Kevin Lobo, President CEO, Director | ||
| Glenn Boehnlein, CFO, Vice President | ||
| Jason Beach, VP Relations | ||
| Spencer Stiles, Group Spine | ||
| Viju Menon, Group President - Global Quality and Business Operations | ||
| Andrew Pierce, Group Neurotechnology | ||
| William Berry, Principal Accounting Officer, Vice President Corporate Controller | ||
| Timothy Scannell, Group President - MedSurg and Neurotechnology |
Stryker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0618 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 101.82 B | |||
| Shares Outstanding | 378.83 M | |||
| Shares Owned By Insiders | 1.79 % | |||
| Shares Owned By Institutions | 80.48 % | |||
| Price To Earning | 20.44 X | |||
| Price To Book | 5.77 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Stryker Stock
When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Stryker Stock please use our How to Invest in Stryker guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.